Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Investor Presentation (September 2021)
12 slides from Alzecure Pharma Ab's investor presentation, Sep 1, 2021
Slide 1: Company Overview & Vision
Company Overview & Vision Martin Jönsson CEO
Slide 2: AlzeCure Pharma
AlzeCure Pharma Founded in 2016, out of a research foundation sponsored by Alzheimerfonden Experienced team with extensive background within Pharma industry Based at Novum Science Park, Karolinska Institute, Stockholm, Sweden Working in Alzheimer’s Disease (AD) and Pain – multi-billion marke
Slide 3: Our Business Model
Our Business Model • We are a Research & Development company • Research & develop through early clinical phase and then out-license our projects • Gain incomes through: − Upfront payments − Milestone payments − Royalties on sold products 32
Slide 4: Small molecule drugs – AlzeCure's approach for increased success
Small molecule drugs – AlzeCure’s approach for increased success DIFFERENCES BETWEEN SMALL MOLECULES & BIOLOGICS* SMALL MOLECULE LARGE BIOLOGIC DRUG AlzeCure focus Monoclonal antibody Small molecule drug c. 25,000 atoms Smaller molecules can have increased likelihood of penetrating the Blood Brain B
Slide 5: A pipeline of small-molecule programs – Multiple candidates increase chance of success
A pipeline of small-molecule programs – Multiple candidates increase chance of success Platform Candidate Indication Research phase Preclinical phase Phase I Phase II Phase III Alzheimer’s Disease, NeuroRestore® Sleep disorders, Ongoing ACD856 Traumatic brain injuries Parkinson’s disease Fully funde
Slide 6: Alzheimer's Disease – Our primary focus area
Our primary Focus area Alzheimer’s Disease • Costs the society more than oncology and cardiovascular diseases TOGETHER • The patient population and costs will TRIPLE in the next 30 years 35
Slide 7: Tripling patient population – due to the aging population
Tripling patient population – due to the aging population 150m 75m 50m 2020 2030 2050 • 50 million people worldwide live with dementia … • … and doubling every 20 years • Alzheimer’s accounts for 60 - 70% of all dementia cases 36
Slide 8: Alzheimer's Disease - Progressive & lethal disorder with lack of available therapies
Alzheimer’s Disease - Progressive & lethal disorder with lack of available therapies Pre-symptomatic Alzheimer’s 10 - 20 years prior to symptoms In Pre-symptomatic Alzheimer’s, Aβ amyloid Symptomatic Alzheimer’s 7 - 10 years life expectancy The stage includes dying neurons in the brain † patholo
Slide 9: Two Alzheimer's platforms - 1st-in-class properties & potential game-changers
Two Alzheimer’s platforms - 1st-in-class properties & potential game-changers TARGET TWO KEY AREAS WITH A HIGH UNMET MEDICAL NEED Disease-modifying therapy Symptomatic therapy Alzstatin® NeuroRestore® Targeting Amyloid Production Improving Neuronal Function - Novel Oral Small Molecule - Novel Oral S
Slide 10: Our platform PAINLESS – Targeting unmet medical needs within pain
Our platform PAINLESS – Targeting unmet medical needs within pain Neuropathic pain* Osteoarthritis & severe pain conditions 25 – 30 million patients > 300 million patients Project: ACD440 Project: TrkA-NAM 39 *) Neuropathic pain = Pain initiated or caused by a primary lesion or dysfunction in the so
Slide 11: Key investment highlights in AlzeCure
Key investment highlights in AlzeCure Targeting areas of huge unmet medical needs m Strong team with extensive experience and track record Platforms with first-in-class properties and potential game-changers Parallel investments in several candidates and potent follow-up programs Multi-billion dolla
Slide 12: Karolinska Institutet Novum Science Park
Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm SWEDEN www.alzecurepharma.com
AlzeCure Pharma — Investor Presentation (September 2021) on 6ix